Market Overview

Aegis Capital Maintains Buy on Trius Therapeutics, Inc., Lowers PT to $14.00

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for TSRX

DateFirmActionFromTo
Aug 2013Aegis CapitalDowngradesBuyHold
Aug 2013GuggenheimDowngradesBuyNeutral
Jul 2013PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for TSRX
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (TSRX)